Navigation Links
Helix BioPharma announces Q1 2008 financial results
Date:12/17/2007

ment collaborations, and other strategic alliances, which, if obtained, may reduce the Company's interest in its projects or products. There can be no assurance, however, that any alternative sources of funding will be available.

The Company's unaudited interim consolidated first quarter fiscal 2007 and 2006 financial statements are summarized below:

-------------------------------------------------------------------------

Consolidated Statements of Operations

for the three month period ended October 31

(thousand $, except for per share data)

2007 2006

---------------------------

Revenue:

Product revenue 754 696

License fees and royalties 131 130

Research and development contracts - -

---------------------------

885 826

Expenses:

Cost of sales 313 290

Research and development 782 871

Operating, general and admin 1,313 906

Amortization of intangibles 7 40

Amortization of capital assets 66 77

Stock-based compensation 12 12

Interest income, net (104) (102)

Foreign exchange loss 108 45

---------------------------

2,497 2,139

Loss before income taxes
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
11. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... , , Nursing Care at Hahnemann ... 16 Hahnemann University Hospital proudly announces it has been ... Magnet Recognition Program(R). Magnet(R) is one of the highest levels ... places Hahnemann among the five percent of hospitals in the ...
... , Toronto biotechnology company,s revenues increase 22% ... in fiscal 2010 , TORONTO, Dec. 16 /PRNewswire-FirstCall/ - ... virology and biological technologies, today reported financial results for ... ended September 30, 2009, Microbix reported revenues of $6.08 ...
... ... Soy Peptone. HSP A has been found to be effectinve in improving yelds of ... (PRWEB) December ... Peptones by introducing HSP-A Soy Peptone. HSP-A, previously manufactured by Nutricepts, Inc. (Burnsville, Mn), ...
Cached Biology Technology:Hahnemann University Hospital Granted Magnet(R) Status 2Hahnemann University Hospital Granted Magnet(R) Status 3Microbix' Pipeline Set To Reach Milestones In 2010 2Microbix' Pipeline Set To Reach Milestones In 2010 3Microbix' Pipeline Set To Reach Milestones In 2010 4Microbix' Pipeline Set To Reach Milestones In 2010 5Microbix' Pipeline Set To Reach Milestones In 2010 6Microbix' Pipeline Set To Reach Milestones In 2010 7Microbix' Pipeline Set To Reach Milestones In 2010 8
(Date:12/17/2014)... Dec. 16, 2014  Automation is fundamentally transforming ... evident than at international borders. Over the past ... have allowed veteran travelers to self process through ... (APC) Kiosks at an increasing number of airports, ... According to Maxine Most , ...
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) ... Market in India 2015-2019" report to their ... in this market is the adoption of multimodal ... one characteristic of an individual for verification and ...
(Date:12/10/2014)... NEW YORK , Dec. 8, 2014 You,ve ... online banking account but can,t remember your password, site key ... birthday? Who was your first grade teacher? ... launches the app that will finally put an ... PINs – 1U TM . 1U leverages a ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... Enerbck, Professor at the Institute of Biomedicine at the Sahlgrenska ... who published their results in The New England Journal ... and others show that adults use brown fat to convert ... possibilities in treating overweight and obesity. It has previously ...
... not for a group of enzymes called topoisomerases, DNA ... a cell as it gets twisted, rolled, unzipped, and ... its sequence. Topoisomerases, which are responsible for relieving ... were first discovered in the 1970s by Harvard,s Professor ...
... the Monell Center report that the red panda is the ... sweetener aspartame. This unexpected affinity for an artificial sweetener ... receptor. The findings may shed light on ... differences in taste receptors. "The red panda,s unique taste ...
Cached Biology News:New book, 'Untangling the Double Helix,' explores enzymes responsible for maintaining genome integrity 2Red pandas reveal an unexpected (artificial) sweet tooth 2Red pandas reveal an unexpected (artificial) sweet tooth 3
... between P-selectin and P-selectin glycoprotein ligand-1 (PSGL-1) ... the lumenal surface of endothelial cells at ... primary role of PSGL-1 in mediating the ... well documented.MAB4092 completely blocks recognition of PSGL-1 ...
Mouse Anti-Human MCAF-(MCP-1)...
Mouse VEGF R1/Flt-1 Phycoerythrin MAb (Clone 141522) Keywords: Receptor Tyrosine Kinase, RTK, VEGFR1, VEGF Receptor 1 Protein Family: Receptor Tyrosine Kinases, VEGF/PDGF Family...
Recognizes Kir4.1. The epitope does not share homology with any other known proteins.,SPECIES REACTIVITIES: The antibody is also expected to work with mouse and human due to sequence homology. Oth...
Biology Products: